Results 161 to 170 of about 98,661 (266)
A giant window-type patent ductus arteriosus with suprasystemic pulmonary hypertension: when shunt burden overrides pressure. [PDF]
Zhou X, Liu H, Hua Z.
europepmc +1 more source
In this single‐center cohort of 856 patients with preserved left ventricular ejection fraction undergoing atrial fibrillation ablation, post‐procedural HFA‐PEFF reassessment provided better long‐term discrimination for heart failure hospitalization than pre‐procedural assessment over a median 5.2‐year follow‐up.
Hironori Ishiguchi +7 more
wiley +1 more source
Myopericarditis Presenting With McConnell's Sign: A Case Report and Literature Review. [PDF]
Rector G, Bilal MF, Maag R.
europepmc +1 more source
ABSTRACT Aims We report 5‐year results from a phase 1/2a study of delandistrogene moxeparvovec, a recombinant adeno‐associated virus serotype rh74 vector‐based gene therapy for Duchenne muscular dystrophy (DMD), with post hoc analyses contextualizing functional outcomes. Methods Four ambulatory patients with DMD (≥ 4–< 8 years at enrollment) entered an
Jerry R. Mendell +10 more
wiley +1 more source
Clinical measurements of aortic stiffness and peripheral resistance using a routine echocardiogram. [PDF]
Gudenkauf M, Kumar S, Manring ND.
europepmc +1 more source
Strategies to Identify Echocardiogram Complexity to Support Learning Echocardiogram Interpretation
Thomas C. Raissi +9 more
openaire +2 more sources
This retrospective cohort study used linked data to measure the proportion of women with rheumatic heart disease (RHD) who experienced major adverse cardiovascular events (MACE) after 20 weeks of gestation. Before birth, 4.5% of women with initially uncomplicated RHD and 31.8% of women with initially complicated RHD experienced RHD‐MACE.
Ingrid Stacey +8 more
wiley +1 more source
Inferior Vena Cava Stenosis Mimicking Right Heart Failure in Carcinoid Heart Disease. [PDF]
Vila-Sanjuán S +9 more
europepmc +1 more source
Abstract Background and Purpose Aberrant activation of type 2 ryanodine receptors (RyR2) causes lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Developing drugs that suppress RyR2 hyperactivation may be key to novel arrhythmia treatments.
Nagomi Kurebayashi +29 more
wiley +1 more source

